Virtual Roundtable Discussion With Key Opinion Leaders in Psychiatry From Harvard and Imperial
Distinguished psychiatrists Jerry Rosenbaum, MD, Professor of Psychiatry at Harvard Medical School, and David Erritzoe, MD, PhD, Imperial College London, joined Small Pharma’s Chief Medical & Scientific Officer, Carol Routledge, PhD to discuss the potential of short-duration psychedelics as a treatment for depression and other mental health conditions. The experts shared insights into:
- Major Depressive Disorder diagnosis, existing treatment options, and long-term management
- The potential of short-duration psychedelics as a clinical treatment for depression and other mental health conditions
- Mental health care delivery and infrastructure implications
Watch the roundtable discussion here.